Rare blood diseases present unique challenges in both diagnostic and therapeutic development due to their limited prevalence and often complex nature. As a research service provider, Protheragen is dedicated to addressing the complexity of rare blood diseases through a comprehensive suite of services including diagnostic and therapeutic development, disease model development, and preclinical research.
Our team is dedicated to identifying new biomarkers, developing innovative detection methods, and in vitro diagnostic (IVD) kits to enhance the accuracy and efficiency of rare blood disease detection. Through a rigorous research and validation process, we aim to provide reliable and effective diagnostic solutions.
We focus on developing novel therapeutic interventions for rare blood diseases, such as small molecule drugs, gene therapies, antibody therapies, etc. Our research team is committed to driving therapeutic innovation through drug discovery, target validation and preclinical development.
Protheragen excels in creating cell-based models, organoid models, and intricate animal models to faithfully replicate the pathology and progression of rare blood diseases. These models serve as invaluable tools for studying disease mechanisms and screening potential drugs.
Our company provides comprehensive preclinical research services, including pharmacodynamics, pharmacokinetics and toxicology assessments. These services help customers test the safety and efficacy of potential therapies, paving the way for their successful translation into clinical practice.
Dedicated to the relentless pursuit of scientific inquiry and technological advancement, our company is deeply immersed in unraveling the intricate complexities of a multitude of rare blood diseases.
| Myeloproliferative Disorders (MPDs) | |
|---|---|
| Chronic Eosinophilic Leukemia (CEL) Chronic Myeloid Leukemia (CML) Chronic Myelomonocytic Leukemia (CMML) Chronic Neutrophilic Leukemia (CNL) Essential Thrombocythemia (ET) Hypereosinophilic Syndrome (HES) |
Mastocytosis Myelodysplastic Syndrome (MDS) Myelofibrosis (MF) Polycythemia Vera (PV) Primary Myelofibrosis (PMF) Thrombocythemia (THCYT) |
| Bone Marrow Failure Syndromes (BMFS) | |
| Congenital Agranulocytosis Congenital Amegakaryocytic Thrombocytopenia (CAMT) Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Dyskeratosis Congenita (DC) Familial Hemophagocytic Lymphohistiocytosis (FHL) Paroxysmal Nocturnal Hemoglobinuria Pearson Syndrome |
Reticular Dysgenesis Severe Congenital Neutropenia (SCN) Short Telomere Syndrome Shwachman-Diamond Syndrome (SDS) Telomere Biology Disorders Thrombocytopenia Absent Radii Syndrome And More |
| Lymphoproliferative Disorders (LPDs) | |
| Adult T-Cell Leukemia/Lymphoma (ATLL) Anaplastic Large Cell Lymphoma (ALCL) Burkitt Lymphoma Chronic Lymphocytic Leukemia (CLL) Cutaneous T-Cell Lymphoma (CTCL) Diffuse Large B-Cell Lymphoma (DLBCL) Extranodal NK/T-Cell Lymphoma, Nasal Type Follicular Lymphoma Hairy Cell Leukemia Hodgkin Lymphoma |
Hemophagocytic Lymphohistiocytosis (HLH) Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma (NHL) Peripheral T-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder (PTLD) Primary Mediastinal B-Cell Lymphoma Waldenström Macroglobulinemia |
| Bleeding Disorders | |
| Acquired Hemophilia A (AHA) Afibrinogenemia Bernard-Soulier Syndrome Ehlers-Danlos Syndrome Glanzmann Thrombasthenia Gray Platelet Syndrome Hemophilia |
Hermansky-Pudlak Syndrome May-Hegglin Anomaly Platelet Storage Pool Disorder Purpura Fulminans (PF) Scott Syndrome Thrombotic Thrombocytopenic Purpura (TTP) Von Willebrand Disease (VWD) |
| Anemia | |
| Alpha-Thalassemia (A-THAL) Aplastic Anemia (AA) Atypical Hemolytic Uremic Syndrome (AHUS) Autoimmune Hemolytic Anemia (AIHA) Beta-Thalassemia (B-THAL) Blackfan-Diamond Anemia Congenital Dyserythropoietic Anemia Diamond-Blackfan Anemia (DBA) Fanconi Anemia (FA) |
Hemolytic Anemia Hereditary Spherocytosis Iron Deficiency Anemia Megaloblastic Anemia Normocytic Anemia Paroxysmal Nocturnal Hemoglobinuria (PNH) Pure Red Cell Aplasia Sickle Cell Disease (SCD) Sideroblastic Anemia |
Protheragen provides tailored one-stop therapeutic development services for rare blood diseases, customized according to the specific needs of our clients. Additionally, we offer a range of specialized products that serve as potent tools for your scientific endeavors, driving forward the field of biomedical research.
Cutting-edge Technology Platforms
Professional Talent Team
Customized Solutions
Rich Experience in Drug Development
High-quality After-sales Service
Reliable Partner
If you are interested in our services, please feel free to contact us for more information.
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)